PUTTINI MIRIAM

Posizione organizzativa: 
Ruolo: 
Tecnico - amministrativo
Telefono: 
0264488035
Stanza: 
U8, Piano: T, Stanza: T018A
Via Cadore, 48 - 20900 MONZA

Pubblicazioni

  • Gambacorti Passerini, C., Antolini, L., Piazza, R., Guilhot, F., Deininger, M., Fava, C., et al. (2011). Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years. In ASH 2011; 53rd Congress of the American Society of Hematology (pp.1608-1608). W.B. Saunders. Dettaglio
  • Gambacorti Passerini, C., Antolini, L., Mahon, F.X., Guilhot, F., Deininger, M., Fava, C., et al. (2011). Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. JOURNAL OF THE NATIONAL CANCER INSTITUTE. Dettaglio
  • Tornaghi, L., Meneghetti, I., Dilda, I., Puttini, M., Piazza, R., Antolini, L., et al. (2009). Imatinib long term effects study: three years of follow-up and assessment. In SIE 2009; 42nd Congress of the Italian Society of Hematology. Il Pensiero Scientifico. Dettaglio
  • Puttini, M., Redaelli, S., Moretti, L., Brussolo, S., Gunby, R., Mologni, L., et al. (2008). Characterization of compound 584, an Abl kinase inhibitor with lasting effects. HAEMATOLOGICA, 93(5), 653-661. Dettaglio
  • Gunby, R.H., Sala, E., Tartari, C.G., Puttini, M., Gambacorti Passerini, C., & Mologni, L. (2007). Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 7(6), 594-611. Dettaglio